Free Trial
NASDAQ:ATNF

180 Life Sciences 5/15/2024 Earnings Report

180 Life Sciences logo
$1.02 -0.01 (-0.97%)
Closing price 05/30/2025 03:58 PM Eastern
Extended Trading
$1.01 -0.01 (-0.78%)
As of 05/30/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

180 Life Sciences EPS Results

Actual EPS
-$1.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

180 Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

180 Life Sciences Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

180 Life Sciences' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

180 Life Sciences Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More 180 Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 180 Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 180 Life Sciences and other key companies, straight to your email.

About 180 Life Sciences

180 Life Sciences (NASDAQ:ATNF), a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

View 180 Life Sciences Profile

More Earnings Resources from MarketBeat